DIN 02229056 — PROHANCE 279.3 MG
PROHANCE is a solution of Gadoteridol marketed by BRACCO IMAGING CANADA. The full Gadoteridol monograph covers indications, dosing, interactions and counselling for every strength and manufacturer.
- DIN
- 02229056
- Brand name
- PROHANCE
- Active ingredient
- Gadoteridol
- Strength
- 279.3 MG
- Dosage form
- SOLUTION
- Route
- INTRAVENOUS
- Manufacturer
- BRACCO IMAGING CANADA
- Health Canada status
- MARKETED
- Drug class
- Gadolinium-based contrast agent (macrocyclic, nonionic MRI contrast medium)
Product data from the Health Canada Drug Product Database, synced . Verify the live status at Health Canada.